Katsandri Anastasia, Avlamis Athina, Pantazatou Angeliki, Petrikkos Georgios L, Legakis Nicholas J, Papaparaskevas Joseph
Department of Microbiology, Laikon General Hospital, 11527 Athens, Greece.
Diagn Microbiol Infect Dis. 2006 Jul;55(3):231-6. doi: 10.1016/j.diagmicrobio.2006.01.022. Epub 2006 Apr 19.
The in vitro activity of tigecycline was compared with those of benzylpenicillin, piperacillin + tazobactam, cefoxitin, imipenem, metronidazole, clindamycin, and tetracycline against 249 Gram-negative anaerobic bacteria (158 Bacteroides fragilis group, 27 non-fragilis Bacteroides spp., 44 Prevotella spp., and 20 miscellaneous), recently isolated from 8 general hospitals in Athens, Greece. Overall tigecycline MIC(50) and MIC(90) were 0.25 and 2 mg/L, respectively, whereas B. fragilis group MIC(50) and MIC(90) were 0.5 and 4 mg/L, respectively. In total, 93% of the isolates were susceptible to tigecycline (MIC </= 4 mg/L) and no high-level resistance (MIC >/= 32 mg/L) was detected. In addition, tigecycline exhibited good activity against metronidazole- and tetracycline-resistant isolates (MIC(90), 0.5 and 8 mg/L, respectively). In summary, tigecycline exhibits good in vitro activity against Gram-negative anaerobic bacteria isolated in Greece, as well as stability to the most common occurring resistance mechanisms, attributes that make this parenteral agent an attractive alternative for use against infections involving these microorganisms.
将替加环素的体外活性与苄青霉素、哌拉西林+他唑巴坦、头孢西丁、亚胺培南、甲硝唑、克林霉素和四环素针对249株革兰氏阴性厌氧菌（158株脆弱拟杆菌群、27株非脆弱拟杆菌属、44株普雷沃菌属和20株其他菌属）的活性进行了比较，这些菌株最近从希腊雅典的8家综合医院分离得到。总体而言，替加环素的MIC（50）和MIC（90）分别为0.25和2mg/L，而脆弱拟杆菌群的MIC（50）和MIC（90）分别为0.5和4mg/L。总共93%的分离株对替加环素敏感（MIC≤4mg/L），未检测到高水平耐药（MIC≥32mg/L）。此外，替加环素对甲硝唑和四环素耐药的分离株也表现出良好活性（MIC（90）分别为0.5和8mg/L）。总之，替加环素对在希腊分离得到的革兰氏阴性厌氧菌表现出良好的体外活性，以及对最常见耐药机制的稳定性，这些特性使这种胃肠外用药成为治疗涉及这些微生物感染的有吸引力的替代药物。
